vinorelbine + capecitabine

Vinorelbine + capecitabine is a combination chemotherapy regimen consisting of two small molecule antineoplastic agents. Vinorelbine is a semi-synthetic vinca alkaloid that inhibits microtubule assembly, thereby disrupting mitosis and leading to cell death. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), which interferes with DNA synthesis by inhibiting thymidylate synthase, resulting in impaired DNA replication and cell death. This combination has been studied for the treatment of metastatic breast cancer and other solid tumors, often as an oral regimen or with intravenous administration of vinorelbine[1][2].

Brand names

NavelbineXeloda

Other names

capecitabine and vinorelbine